Management of severe chronic spontaneous urticaria with omalizumab

Omalizumab (OMA) is effective in chronic spontaneous urticaria (CSU), but some individuals do not respond to the standard dose (300 mg/month) or require treatment for a longer period (>6 months). We aimed to identify biomarkers predictive of the need for longer OMA treatment or for OMA updosing.

Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Laura Zubiaga Fernandez, Julia Rodriguez de Guzman Cejudo, Joan Bartra, Marta Ferrer, Maria Torres Jaen, Almudena Testera Montes, Carmen Rondon Segovia, Natalia Perez Sanchez, Ibon Eguiluz Source Type: research